Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors

Journal of Biomolecular Screening

Volumn 17, Issue 7, 2012, Pages 957-965

  Ahmad, Syed ^a   Hughes, Mark A ^a   Yeh, Li An ^a   Scott, John E ^a  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

glucuronidase; amoxapine; CPT 11; irinotecan; isocarboxazid; mefloquine; nialamide; phenelzine

Indexed keywords

AMOXAPINE; BETA GLUCURONIDASE; FIRTECAN; GLYCOSIDASE INHIBITOR; ISOCARBOXAZID; LOXAPINE; MEFLOQUINE; NIALAMIDE; PHENELZINE;

ARTICLE; BACTERIOSTASIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ESCHERICHIA COLI; GLUCURONIDATION; IC 50; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AMOXAPINE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GLUCURONIDASE; ISOCARBOXAZID; MEFLOQUINE; MONOAMINE OXIDASE INHIBITORS; NIALAMIDE; PHENELZINE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MAMMALIA;

EID: 84863848253     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057112444927     Document Type: Article

References (29)

1. Pommier Y.. Topoisomerase I Inhibitors: Camptothecins and Beyond. Nat. Rev. Cancer. 2006 ; 6: 789-802 (Pubitemid 44450467)
2. Pizzolato J. F., Saltz L. B.. The Camptothecins. Lancet. 2003 ; 361: 2235-2242 (Pubitemid 36782561)
3. Smith N. F., Figg W. D., Sparreboom A.. Pharmacogenetics of Irinotecan Metabolism and Transport: An Update. Toxicol. In Vitro. 2006 ; 20: 163-175 (Pubitemid 43087700)
4. Ma M. K., McLeod H. L.. Lessons Learned from the Irinotecan Metabolic Pathway. Curr. Med. Chem. 2003 ; 10: 41-49 (Pubitemid 36131648)
5. Mathijssen R. H. J., van Alphen R. J., Verweij J., Loos W. J., Nooter K., Stoter G., Sparreboom A.. Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11). Clin Cancer Res. 2001 ; 7: 2182-2194 (Pubitemid 32751614)
6. Miley M. J., Zielinska A. K., Keenan J. E., Bratton S. M., Radominska-Pandya A., Redinbo M. R.. Crystal Structure of the Cofactor-Binding Domain of the Human Phase II Drug-Metabolism Enzyme UDP-Glucuronosyltransferase 2B7. J. Mol. Biol. 2007 ; 369: 498-511 (Pubitemid 46678060)
7. Nagar S., Blanchard R. L.. Pharmacogenetics of Uridine Diphosphoglucuronosyltransferase (UGT) 1A Family Members and Its Role in Patient Response to Irinotecan. Drug Metab. Rev. 2006 ; 38: 393-409 (Pubitemid 44167197)
8. Stein A., Voigt W., Jordan K.. Review: Chemotherapy-Induced Diarrhea: Pathophysiology, Frequency and Guideline-Based Management. Ther. Adv. Med. Oncol. 2010 ; 2: 51-63
9. Tobin P. J., Dodds H. M., Clarke S., Schnitzler M., Rivory L. P.. The Relative Contributions of Carboxylesterase and Beta-Glucuronidase in the Formation of SN-38 in Human Colorectal Tumours. Oncol. Rep. 2003 ; 10: 1977-1979
10. Hu Z. P., Yang X. X., Chan S. Y., Xu A. L., Duan W., Zhu Y. Z., Sheu F. S., Boelsterli U. A., Chan E., Zhang Q., Wang J. C., Ee P. L., Koh H. L., Huang M., Zhou S. F.. St. John's Wort Attenuates Irinotecan-Induced Diarrhea via Down-Regulation of Intestinal Pro-inflammatory Cytokines and Inhibition of Intestinal Epithelial Apoptosis. Toxicol. Appl. Pharmacol. 2006 ; 216: 225-237 (Pubitemid 44466003)
11. Kurita A., Kado S., Matsumoto T., Asakawa N., Kaneda N., Kato I., Uchida K., Onoue M., Yokokura T.. Streptomycin Alleviates Irinotecan-Induced Delayed-Onset Diarrhea in Rats by a Mechanism Other Than Inhibition of Beta-Glucuronidase Activity in Intestinal Lumen. Cancer Chemother. Pharmacol. 2011 ; 67: 201-213
12. Basinska A., Florianczyk B.. Beta-Glucuronidase in Physiology and Disease. Annales Universitatis Mariae Curie-Sklodowska. 2003 ; 58: 386-389
13. Farnleitner A. H., Hocke L., Beiwl C., Kavka G. C., Mach R. L.. Hydrolysis of 4-Methylumbelliferyl-beta-D-glucuronide in Differing Sample Fractions of River Waters and Its Implication for the Detection of Fecal Pollution. Water Res. 2002 ; 36: 975-981 (Pubitemid 34019246)
14. Wallace B. D., Wang H., Lane K. T., Scott J. E., Orans J., Koo J. S., Venkatesh M., Jobin C., Yeh L. A., Mani S., Redinbo M. R.. Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme. Science. 2010 ; 330: 831-835
15. Ahmad S., Hughes M. A., Lane K. T., Redinbo M. R., Yeh L. A., Scott J. E.. A High Throughput Assay for Discovery of Bacterial Beta-Glucuronidase Inhibitors. Curr. Chem. Genomics. 2011 ; 5: 13-20
16. McGovern S. L., Caselli E., Grigorieff N., Shoichet B. K.. A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening. J. Med. Chem. 2002 ; 45: 1712-1722 (Pubitemid 34293537)
17. Feng B. Y., Simeonov A., Jadhav A., Babaoglu K., Inglese J., Shoichet B. K., Austin C. P.. A High-Throughput Screen for Aggregation-Based Inhibition in a Large Compound Library. J. Med. Chem. 2007 ; 50: 2385-2390 (Pubitemid 46799249)
18. Tobin P., Clarke S., Seale J. P., Lee S., Solomon M., Aulds S., Crawford M., Gallagher J., Eyers T., Rivory L.. The In Vitro Metabolism of Urinotecan (CPT-11) by Carboxylesterase and Beta-Glucuronidase in Human Colorectal Tumours. Br. J. Clin. Pharmacol. 2006 ; 62: 122-129 (Pubitemid 44195248)
19. Prijovich Z. M., Chen K. C., Roffler S. R.. Local Enzymatic Hydrolysis of an Endogenously Generated Metabolite Can Enhance CPT-11 Anticancer Efficacy. Mol. Cancer Ther. 2009 ; 8: 940-946
20. Huang P. T., Chen K. C., Prijovich Z. M., Cheng T. L., Leu Y. L., Roffler S. R.. Enhancement of CPT-11 Antitumor Activity by Adenovirus-Mediated Expression of Beta-Glucuronidase in Tumors. Cancer Gene Ther. 2011 ; 18: 381-389
21. Ulus I. H., Maher T. J., Wurtman R. J.. Characterization of Phentermine and Related Compounds as Monoamine Oxidase (MAO) Inhibitors. Biochem. Pharmacol. 2000 ; 59: 1611-1621 (Pubitemid 30229896)
22. Maxwell D. R., Gray W. R., Taylor E. M.. Relative Activity of Some Inhibitors of Mono-amine Oxidase in Potentiating the Action of Tryptamine In Vitro and In Vivo. Br. J. Pharmacol. Chemother. 1961 ; 17: 310-320
23. Lexchin J.. Drug Withdrawals from the Canadian Market for Safety Reasons, 1963-2004. CMAJ. 2005 ; 172: 765-767 (Pubitemid 40388735)
24. Wimbiscus M., Kostenko O., Malone D.. MAO Inhibitors: Risks, Benefits, and Lore. Cleve. Clin. J. Med. 2010 ; 77: 859-882
25. Fisch M.. Treatment of Depression in Cancer. J. Natl. Cancer Inst. Monogr. 2004: 105-111
26. Palmeira A., Rodrigues F., Sousa E., Pinto M., Vasconcelos M. H., Fernandes M. X.. New Uses for Old Drugs: Pharmacophore-Based Screening for the Discovery of P-Glycoprotein Inhibitors. 2011. Chem. Biol. Drug Des. 2011 ; 78: 57-72
27. Leonard B. E.. Pharmacology of New Antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1984 ; 8: 97-108 (Pubitemid 14126061)
28. Badway M. A., Dugas J. E.. Loxapine Yields Amoxapine. J. Clin. Psychopharmacol. 1984 ; 4: 363-364
29. Cheung S. W., Tang S. W., Remington G.. Simultaneous Quantitation of Loxapine, Amoxapine and Their 7- and 8-Hydroxy Metabolites in Plasma by High-Performance Liquid Chromatography. J. Chromatogr. 1991 ; 564: 213-221